Solara Active Pharma Q1 2026: Revenue up 15%, PAT peak

What Solara reported for the quarter

Solara Active Pharma Sciences Limited reported a stronger start to the year, led by quarter-on-quarter growth and a return to profit. The company reported Q1 revenue of about ₹320 crore, with one results summary putting revenue at ₹320.00 crore and another at ₹319.15 crore. Both summaries describe revenue growth of roughly 15% quarter-on-quarter. EBITDA for the quarter was reported at ₹57.00 crore in one snapshot, while another section references EBITDA of about ₹58.00 crore.

The headline change was at the bottom line, where Solara posted a net profit of ₹10.52 crore versus a loss of ₹13.46 crore in the same quarter last year. The company also described this as its highest profit after tax (PAT) in 12 quarters. Management commentary in the provided text links the quarter’s improvement to a shift towards regulated markets, cost controls, and continued efforts to reduce debt.

Revenue growth and what the QoQ numbers imply

The report flags quarter-on-quarter revenue growth of 15%, and one section quantifies this as a rise to ₹319.15 crore from ₹273.01 crore. That same section also states that the year-on-year change for revenue was negative, with a YoY decline of 12.20%. This split between sequential improvement and annual decline frames the quarter as a recovery in run-rate rather than a full cyclical turnaround.

Operationally, the company’s narrative emphasises a move away from lower-margin exposure and a tighter approach to pricing and product mix. Solara’s management also referenced the impact of competition in the ibuprofen range, which had weighed on performance earlier. The tone of the commentary suggests the company is prioritising margin discipline even if that means a slower revenue ramp-up.

Margin expansion: gross margin and EBITDA margin

Solara reported a sharp year-on-year improvement in gross margin and EBITDA margin for the quarter. Gross margin improved by 960 basis points YoY to 54.10%. EBITDA margin rose by 640 basis points YoY to 18.00%. In parallel, the company reported EBITDA growth of 13% quarter-on-quarter to ₹57.00 crore.

Management commentary attributes margin expansion to higher exposure to regulated markets, a reduced reliance on plain ibuprofen, and stronger contribution from higher-margin products. The company also highlighted ongoing cost control measures as a structural lever supporting profitability.

Profitability swing: loss to profit

The quarter marked a clear swing in profitability. Net profit stood at ₹10.52 crore, compared with a net loss of ₹13.46 crore in the corresponding quarter last year. Another portion of the provided text also presents a profitability bridge versus the immediate previous quarter, stating net profit at ₹10.52 crore compared to ₹-2.10 crore in the prior quarter.

While the text includes additional profit tables and quarterly comparisons, the central takeaway stays consistent: the quarter delivered positive earnings after a loss-making period, and management positioned it as part of a broader “reset to growth” phase.

Cost controls, operating discipline, and what changed

A key operational detail in the management discussion is operating cost reduction. The CFO commentary states the company reduced its operating cost base by around 1,300 million year-on-year, which is roughly ₹130 crore. It also states that the quarterly exit run-rate for costs moved from around ₹130 crore in FY24 to about ₹109 crore by FY25 Q4.

The text links cost actions to better operating leverage in FY26, implying that incremental revenue at healthier gross margins can flow through to EBITDA. It also flags working capital as a stress point during muted revenue growth, which in turn contributed to incremental finance cost.

Regulated markets and product mix shift

Solara’s management commentary states regulated markets contribute about 76% of overall business. The company also described steering the portfolio from lower-margin products to more profitable products, and reducing reliance on plain ibuprofen while expanding in ibuprofen derivatives and non-ibuprofen products.

The same commentary references facility compliance, including “some great FDA outcomes,” and indicates plants are in a “good state of control.” The narrative suggests governance and compliance outcomes are being treated as enablers for growth in regulated markets.

Debt reduction, rights issue calls, and balance sheet priorities

The company’s balance sheet messaging is explicit in the provided text. Management noted debt reduction from a historic level of around ₹1,000 crore in FY24 to roughly ₹776 crore as it entered FY25. It also stated that proceeds from the first call money of the rights issue are expected to be used to reduce debt further to around ₹650 crore by end of May.

Separately, the company plans to raise ₹134.99 crore through pending rights issue calls. Management also shared a longer-range leverage target, stating that by Q1 FY27, net debt to EBITDA is expected to be in the range of 1.7 to 1.8, subject to shareholder and statutory approvals. In addition, once a new “CRAMS and Polymers” entity is carved out (subject to regulatory approvals), the company discussed the possibility of pushing down about ₹200 crore of debt to the new entity to lighten the catalog business balance sheet.

Outlook and management actions

Management stated it is not giving formal guidance and is instead providing an outlook. The outlook referenced in the text includes top line growth of around 10% and EBITDA growth of around 15% to 20% during FY26. Another section also mentions an internal target framework referencing revenue of around ₹1,500 crore and an EBITDA run rate of about ₹260 crore to ₹290 crore, along with an exit run rate of about ₹80 crore.

In governance updates, Solara also appointed a new Chief Risk Officer, aligning with the company’s repeated emphasis on governance and tighter financial discipline.

Key numbers at a glance

Why this quarter matters for investors

The quarter combines three elements that investors typically track in turnaround cycles: sequential revenue growth, margin expansion, and a return to profit. The profitability swing is supported in the text by product mix changes and cost reduction, rather than a single one-off item. The focus on regulated markets and governance, including a Chief Risk Officer appointment, also fits the company’s positioning around durable operating improvement.

At the same time, the provided material shows the company is still managing through competitive pressure in ibuprofen and working capital constraints. Debt reduction remains central to the plan, and the rights issue inflows are framed as a near-term lever to lower borrowings.

Closing summary

Solara Active Pharma Sciences’ Q1 performance shows a higher revenue run-rate quarter-on-quarter, improved margins, and a return to positive PAT at ₹10.52 crore. Management’s next milestones, as described in the text, include executing rights issue call proceeds, continuing debt reduction, and pursuing the CRAMS and Polymers carve-out subject to regulatory approvals.